BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7683352)

  • 1. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
    Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors.
    Backx B; Broeders L; Touw I; Löwenberg B
    Leukemia; 1993 Jan; 7(1):75-9. PubMed ID: 8418382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
    Suwanawiboon B; Sumida KN
    Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes.
    Carlo-Stella C; Cazzola M; Bernasconi P; Bergamaschi G; Dezza L; Pedrazzoli P; Rosti V; Tomaselli S; Zappone E
    Haematologica; 1989; 74(2):181-6. PubMed ID: 2501171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
    Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
    Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.
    Lee EJ; Hogge DE; Gallagher R; Schiffer CA
    Leukemia; 1990 Dec; 4(12):835-8. PubMed ID: 1700839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU
    Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
    Moon JH; Lee SJ; Lee YJ; Kang BW; Chae YS; Kim JG; Suh JS; Sohn SK
    Ann Hematol; 2012 Mar; 91(3):367-73. PubMed ID: 21947085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.